Role Of Montelukast In Management Of COVID 19
Phase 3
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/11/029232
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients above the age of 14 years both males and females, admitted with a
diagnosis of mild or moderate COVID -19 (on the basis of a positive RT-PCR report) at our facility
during the study period (01/09/2020-31/12/2020)
Exclusion Criteria
1. Patients with a known allergy to or adverse drug reaction with Montelukast.
2. Patients unable to provide consent or unwilling to participate in the study.
3. Patients included in any other ongoing trial will be excluded from the study.
4. Patients below the age of 14 years will be excluded from the study.
5. Pregnant and Lactating Females will be excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Progression of the disease to severe grade. <br/ ><br>2. Admission to ICU . <br/ ><br> <br/ ><br>3. Need for mechanical ventilation. <br/ ><br>4. In-hospital mortalityTimepoint: At every week
- Secondary Outcome Measures
Name Time Method when Patient becomes asymptomatic .Timepoint: At 2 to 4 weeks